Evidence map›Paper›PMID 39255790›Full record

ArticleCell genomics2024

Pooled endogenous protein tagging and recruitment for systematic profiling of protein function.

Yevgeniy V Serebrenik, Deepak Mani, Timothé Maujean, George M Burslem, Ophir Shalem

Abstract read
In one paragraph

Article in Cell genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Designing the Proteome with Chemical Tools: Degrons and Beyond.Chembiochem : a European journal of chemical biology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Yevgeniy V SerebrenikCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Deepak ManiCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Timothé MaujeanDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
George M BurslemDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: george.burslem@pennmedicine.upenn.edu.
Ophir ShalemCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: shalemo@upenn.edu.

Funding

Direct and rapid control of proteins at scaleDP2GM137416 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2022
$2.8M
Editing Acetylation and Protein HomeostasisR35GM142505 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI George Burslem · 2021 to 2026
$2.7M
Dissecting the mechanisms that underlie mislocalization and aggregation of RNA binding proteins in neurodegenerative diseasesR03NS111447 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2019
$352k
Uncovering cell factors with aggregate clearance activity by scalable induced proximityK99AG075256 · NIA · CHILDREN'S HOSP OF PHILADELPHIA · PI SEREBRENIK, YEVGENIY VLADIMIROVICH · 2022 to 2023
$259k
Rapid and direct control of the proteome through a multiplexed tag systemF32CA239499 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI SEREBRENIK, YEVGENIY VLADIMIROVICH · 2019 to 2021
$195k
NCI NIH HHS F32 CA239499NIA NIH HHS K99 AG075256NIGMS NIH HHS DP2 GM137416NIGMS NIH HHS R35 GM142505NINDS NIH HHS R03 NS111447
6 · The paper itself

Abstract

The emerging field of induced proximity therapeutics, which involves designing molecules to bring together an effector and target protein-typically to induce target degradation-is rapidly advancing. However, its progress is constrained by the lack of scalable and unbiased tools to explore effector-target protein interactions. We combine pooled endogenous gene tagging using a ligand-binding domain with generic small-molecule-based recruitment to screen for induction of protein proximity. We apply this methodology to identify effectors for degradation in two orthogonal screens: using fluorescence to monitor target levels and a cellular growth that depends on the degradation of an essential protein. Our screens revealed new effector proteins for degradation, including previously established examples, and converged on members of the C-terminal-to-LisH (CTLH) complex. We introduce a platform for pooled induction of endogenous protein-protein interactions to expand our toolset of effector proteins for protein degradation and other forms of induced proximity.

Indexed as

ProteolysisHEK293 CellsHumansProtein BindingProtein Interaction MappingProteinsProteinsCTLHfunctional proteomicsinduced proximitypooled taggingtargeted protein degradationWDR26

Identifiers

PMID39255790
PMCPMC11602618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.